Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep293 | Calcium and Vitamin D metabolism | ECE2015

An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1 infected women independently of protease inhibitors therapy

Pepe Jessica , Mezzaroma Ivano , Fantauzzi Alessandra , Falciano Mario , Salotti Alessandra , Di Traglia Mario , Diacinti Daniele , Belcastro Sara , Piemonte Sara , Cipriani Cristiana , Minisola Salvatore

Introduction: The best repletion and maintenance dosing regimens with cholecalciferol in vitamin D deficient HIV-1 patients remain unknown. Protease inhibitors (PIs) have been shown to inhibit vitamin D 1α- and 25α-hydroxylation in hepatocyte and monocyte cultures. We therefore evaluated the effect of a single high dose of cholecalciferol in vitamin D deficient HIV-1 postmenopausal women undergoing treatment with highly Active Anti-Retroviral Therapy (cART), with and...

ea0081rc11.3 | Rapid Communications 11: Thyroid 2 | ECE2022

Is the pre-conceptional TSH optimization useful in women submitted to assisted reproduction technology?

Maria Vannucchi Guia , Campi Irene , Cagnina Serena , Covelli Danila , Persani Luca , Mignini Renzini Mario , Fugazzola Laura

Background: thyroid function (TSH levels) and thyroid autoimmunity are involved in the immunomodulation of early pregnancy stages and can affect assisted reproductive technology (ART).Aims: 1) to evaluate if pre-conceptional TSH is associated with an increased risk of miscarriage, 2) to identify a TSH cut-off significantly associated with risk of miscarriage, 3) to assess the impact of TSH levels on primary and surrogate outcomes.M...

ea0081p587 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

GLP-1 and glucagon depict complementary actions on visceral adipose tissue that could mediate metabolic shifts towards catabolism

Morais Tiago , Seabra Alexandre , Patricio Barbara , Guimaraes Marta , Nora Mario , Oliveira Pedro , Alves Marco , Monteiro Mariana

Visceral adipose tissue (VAT) metabolic fingerprints differ according to the individual’s BMI and glycemic status. GLP-1 and Glucagon are two hormones that participate in energy homeostasis and glycemic control. Dual GLP-1/Glucagon agonists are a drug class under development for obesity and diabetes treatment. Although the pancreas and the liver are considered major GLP-1 and glucagon targets, these hormones act in other tissues, which could contribute for its effects on ...

ea0081p394 | Environmental Endocrinology | ECE2022

Synergism between bisphenol a exposure and overweight/obesity in increasing the malignancy risk in a cohort of patients with thyroid nodules

Marotta Vincenzo , Grumetto Lucia , Neri Ilaria , Russo Giacomo , Tortora Anna , Izzo Giulia , Rocco Domenico , Vitale Mario

Introduction: The plasticizer Bisphenol A (BPA) is an endocrine disruptor with thyroid interfering activity. Obesity is a recognized risk factor for thyroid cancer. A recent study showed that subjects with BMI ≥ 25 are more prone to BPA-related thyroid disruption. To date, few and controversial experimental and epidemiological data provide weak evidence about a correlation between BPA exposure and thyroid cancer development. Aim of the present study was to assess a possi...

ea0081ep789 | Pituitary and Neuroendocrinology | ECE2022

GH provocative tests stimulate the growth in children without GH deficiency

Tortora Anna , Marotta Vincenzo , Izzo Giulia , Rocco Domenico , Clemente Gennaro , Vitale Mario

Introduction: GH deficiency (GHD) is a clinical disorder characterized by pathological short stature in the child, altered body composition, impaired psychological well-being and reduced quality of life. These alterations are almost always reversible after recombinant human GH (rhGH) administration, which is currently the only accepted treatment for the subjects with GHD. Secretory dysfunction is confirmed when GH peak does not reach the established cut-off in at least two dif...

ea0050p253 | Neoplasia, Cancer and Late Effects | SFEBES2017

Challenges in diagnosis and management of tumour induced oncogenic osteomalacia

Sewell Gavin , Qureshi Sheharyar , Aslam Roohi , Lepore Mario , Patel Bhavik , Nimri Adib , Kaushal Rashmi

The combination of hypophosphataemia and hypercalcaemia has numerous aetiologies, which can be challenging in the clinical setting. Careful early biochemical identification will facilitate appropriate further imaging and management. We report a case of a gentleman who presented in his ninth decade with deteriorating cognition, proximal muscle weakness and reduced mobility on a background of hypertension, type 2 diabetes with associated ...

ea0050p253 | Neoplasia, Cancer and Late Effects | SFEBES2017

Challenges in diagnosis and management of tumour induced oncogenic osteomalacia

Sewell Gavin , Qureshi Sheharyar , Aslam Roohi , Lepore Mario , Patel Bhavik , Nimri Adib , Kaushal Rashmi

The combination of hypophosphataemia and hypercalcaemia has numerous aetiologies, which can be challenging in the clinical setting. Careful early biochemical identification will facilitate appropriate further imaging and management. We report a case of a gentleman who presented in his ninth decade with deteriorating cognition, proximal muscle weakness and reduced mobility on a background of hypertension, type 2 diabetes with associated ...

ea0084ps1-01-08 | COVID & Thyroid Disease | ETA2022

Graves’ orbitopathy and subacute thyroiditis related to SARS-CoV-2 infection or vaccination: the experience of a single centre in milan, italy

Muller Ilaria , Crivicich Erica , Di Marco Francesco , Curro Nicola , Arosio Maura , Salvi Mario

Background: The Covid-19 pandemic caused by the severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) determined millions of deaths worldwide, thus at the end of 2020 a massive vaccination campaign has been launched. SARS-CoV-2 infection and vaccines have been associated with several thyroid disorders, especially subacute thyroiditis (SAT), Graves’ disease (GD) and orbitopathy (GO). We studied the occurrence of SAT and GO following SARS-CoV-2 infection or vaccinati...

ea0084ps3-12-112 | Graves’ Disease 2 and Orbitopathy | ETA2022

Alemtuzumab-induced graves’ orbitopathy successfully treated with a single dose of rituximab

Di Marco Francesco , Porcaro Laura , Crivicich Erica , Curro Nicola , Arosio Maura , Muller Ilaria , Salvi Mario

Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves’ disease (GD) accounting for 63-65% of cases. Graves’ Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...

ea0084ps3-13-118 | Pregnancy & Iodine | ETA2022

Which is the best pre-conceptional TSH cut-off in women submitted to assisted reproductive technology?

Vannucchi Guia , Campi Irene , Cagnina Serena , Covelli Danila , Mignini Renzini Mario , Persani Luca , Fugazzola Laura

TSH is involved in the immunomodulation of early pregnancy stages. Thyroid guidelines have indicated 2.5 mU/l as the best TSH level below which women undergoing assisted reproductive technology (ART) need to be maintained, though this treshold is still controversial. Aims of the present study were to evaluate if pre-conceptional TSH is associated with an increased risk of miscarriage, to identify a TSH cut-off significantly associated with risk of miscarriage and to assess the...